Remove tag behavioural-science
article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Joanna Carlish, managing director, financial services, Tag Americas. Virtual connections.

article thumbnail

Top email calamities to avoid … and how to make an impact instead

pharmaphorum

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. As a general rule, avoid questionable behaviours and opinions especially when you’re representing your company or institution.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

3 The linker is designed to have properties that physically connect the antibody and cytotoxic drug, and facilitate favourable pharmacokinetic behaviour in circulation, as well as controlled release of the cytotoxin once delivered. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs.

article thumbnail

The Covid cash cow – a look at the Covid vaccine sales figures

pharmaphorum

Indeed, the price tags for Pfizer’s and Moderna’s jabs are substantial. The covid vaccine roll out is arguably the best example of why communications, and specifically behavioural science as part of that, plays such a pivotal role in healthcare.”. Pfizer is understood to have charged $19.50 per dose in the US and €19.50

Vaccines 137
article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

BT-474 cell line was gene-edited to incorporate a green fluorescent protein (GFP) tag into late endosomes/lysosomes (green). The requirement for complex medicines to be fluorescently labelled is another limitation of the method – labelling can be a complicated process, and there is a risk that it could change the behaviour of the compounds.